Literature DB >> 9417060

A novel, secreted form of human ADAM 12 (meltrin alpha) provokes myogenesis in vivo.

B J Gilpin1, F Loechel, M G Mattei, E Engvall, R Albrechtsen, U M Wewer.   

Abstract

The ADAM (A Disintegrin And Metalloprotease) family of cell-surface proteins may have an important role in cellular interactions and in modulating cellular responses. In this report we describe a novel, secreted form of human ADAM 12 (meltrin alpha), designated ADAM 12-S (S for short), and a larger, membrane-bound form designated ADAM 12-L (L for long form). These two forms arise by alternative splicing of a single gene located on chromosome 10q26. Northern blotting demonstrated that mRNAs of both forms are abundant in human term placenta and are also present in some tumor cell lines. The ADAM 12-L transcript can also be detected in normal human adult skeletal, cardiac, and smooth muscle. Human A204 embryonal rhabdomyosarcoma cells that do not differentiate into muscle cells and do not express any form of ADAM 12 were stably transfected with an ADAM 12-S minigene encoding the disintegrin domain, the cysteine-rich domain, and the unique 34 amino acid carboxyl terminus. Nude mouse tumors derived from these transfected cells contained ectopic muscle cells of apparent mouse origin as shown by species-specific markers. These results may have potential applications in the development of muscle-directed gene and cell therapies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9417060     DOI: 10.1074/jbc.273.1.157

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  66 in total

1.  Membrane-anchored metalloprotease MDC9 has an alpha-secretase activity responsible for processing the amyloid precursor protein.

Authors:  H Koike; S Tomioka; H Sorimachi; T C Saido; K Maruyama; A Okuyama; A Fujisawa-Sehara; S Ohno; K Suzuki; S Ishiura
Journal:  Biochem J       Date:  1999-10-15       Impact factor: 3.857

2.  Metalloprotease-disintegrin ADAM 12 binds to the SH3 domain of Src and activates Src tyrosine kinase in C2C12 cells.

Authors:  Q Kang; Y Cao; A Zolkiewska
Journal:  Biochem J       Date:  2000-12-15       Impact factor: 3.857

3.  Metalloprotease-disintegrin ADAM 12 interacts with alpha-actinin-1.

Authors:  Y Cao; Q Kang; A Zolkiewska
Journal:  Biochem J       Date:  2001-07-15       Impact factor: 3.857

4.  Metalloproteases and adipogenesis: a weighty subject.

Authors:  Jennifer Lilla; Dominique Stickens; Zena Werb
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

5.  Selective inhibition of ADAM12 catalytic activity through engineering of tissue inhibitor of metalloproteinase 2 (TIMP-2).

Authors:  Marie Kveiborg; Jonas Jacobsen; Meng-Huee Lee; Hideaki Nagase; Ulla M Wewer; Gillian Murphy
Journal:  Biochem J       Date:  2010-08-15       Impact factor: 3.857

6.  A disintegrin and metalloprotease protein-12 as a novel marker for the diagnosis of ectopic pregnancy.

Authors:  Mary E Rausch; Lynn Beer; Mary D Sammel; Peter Takacs; Karine Chung; Alka Shaunik; David Speicher; Kurt T Barnhart
Journal:  Fertil Steril       Date:  2011-02-01       Impact factor: 7.329

7.  Z-DNA-forming silencer in the first exon regulates human ADAM-12 gene expression.

Authors:  Bimal K Ray; Srijita Dhar; Arvind Shakya; Alpana Ray
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-20       Impact factor: 11.205

8.  Elevated urinary ADAM12 protein levels in lithium-treated bipolar patients.

Authors:  C Nadri; Y Bersudsky; R H Belmaker; G Agam
Journal:  J Neural Transm (Vienna)       Date:  2006-10-27       Impact factor: 3.575

9.  ADAM12 and alpha9beta1 integrin are instrumental in human myogenic cell differentiation.

Authors:  Peggy Lafuste; Corinne Sonnet; Bénédicte Chazaud; Patrick A Dreyfus; Romain K Gherardi; Ulla M Wewer; François-Jérôme Authier
Journal:  Mol Biol Cell       Date:  2004-12-01       Impact factor: 4.138

10.  Transgenic overexpression of ADAM12 suppresses muscle regeneration and aggravates dystrophy in aged mdx mice.

Authors:  Louise Helskov Jørgensen; Charlotte Harken Jensen; Ulla M Wewer; Henrik Daa Schrøder
Journal:  Am J Pathol       Date:  2007-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.